The phase 3 GEMINI-1 and -2 trials (NCT05352893 and NCT05366855) assessed the IL-36 receptor antibody imsidolimab in GPP. In GEMINI-1, 45 adult participants with moderate-to-severe GPP flare were randomised to a single dose of intravenous imsidolimab at 750 mg, 300 mg, or placebo with a primary endpoint of GPPPGA score 0/1 at week 4. Participants could then roll over to GEMINI-2. Responders were re-randomised to subcutaneous imsidolimab maintenance 200 mg every 4 weeks or placebo, while non-responders with prior placebo received a high dose of intravenous imsidolimab followed by 200 mg subcutaneous.
At week 4, significantly more participants achieved the primary endpoint of GPPPGA 0/1 with 1 dose of 750 mg imsidolimab (53.4%) compared with placebo (13.3%; P=0.0131). The response rate for 300 mg was 53.3%. As for flare prevention over at least 24 weeks, assessed in GEMINI-2, all participants on imsidolimab maintained GPPPGA 0/1 without flaring. On placebo, 25% sustained GPPPGA 0/1 and 62.5% experienced a flare. Statistical significance for the difference was irrespective of an initial single dosage before maintenance (750 mg intravenous/200 mg subcutaneous vs placebo P=0.0145; 300 mg intravenous/200 mg subcutaneous P=0.0121).
“Regarding the safety and tolerability, treatment-emergent adverse events were similar in both groups,” Prof. Adam Reich (Medical College of Rzeszow, Poland) announced, adding that no serious adverse events led to treatment discontinuation and the incidence of infection was low.
“We may say that imsidolimab represents a promising therapeutic option for patients with moderate to severe GPP,” Prof. Reich concluded.
- Reich A, et al. Imsidolimab, an IL-36 receptor antagonist, was effective and well tolerated for treatment and prevention of flares in patients with generalised pustular psoriasis: results from the phase 3 trials, GEMINI-1 and GEMINI-2. EPS06.05, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support was provided by Karin Drooff MPH
Posted on
Previous Article
« Prurigo nodularis: long-term treatment reduces relapse events Next Article
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa »
« Prurigo nodularis: long-term treatment reduces relapse events Next Article
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
October 9, 2019
The underestimated effect of visible light
October 9, 2019
New guidance on rosacea therapy according to phenotype
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com